Skip to content
TriangleGet started
← Full study record

NCT01724177 · OUTCOME

Time to Response

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma · Source last updated 2018-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
weeks
Interval / dispersion
Full Range
Time frame
From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks

What was measured

Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR)

Analysis population: Participants with a response of PR or better.

Groups in this outcome

Lenalidomide

Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Lenalidomide11

Reported measurements

Source class 1
Values in weeks · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Lenalidomide8.10Not reported7.916.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7.9
        upper Limit
        16.0
        value
        8.10
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
description
Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR)
dispersion Type
Full Range
groups
  1. description
    Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity
    id
    OG000
    title
    Lenalidomide
param Type
MEDIAN
population Description
Participants with a response of PR or better.
reporting Status
POSTED
time Frame
From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
title
Time to Response
type
OTHER_PRE_SPECIFIED
unit Of Measure
weeks

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice